Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 4/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 2/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543708 | 0.95 | BCHE (0.59) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL5543659 | 0.94 | MGLL (0.59) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL5543691 | 0.94 | MGLL (0.59) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL5543897 | 0.91 | FFAR1 (0.58) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL5543489 | 0.89 | FFAR1 (0.59) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL5545861 | 0.86 | FFAR1 (0.61) | FFAR1MGLL | |
| SCHEMBL5542304 | 0.86 | FFAR1 (0.61) | FFAR1MGLL | |
| SCHEMBL5534673 | 0.86 | FFAR1 (0.61) | FFAR1MGLL | |
| SCHEMBL5536627 | 0.85 | CYP4F2 (0.57) | BCHEFFAR1MGLL | |
| SCHEMBL27373 | 0.85 | IDO1 (0.55) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | LTA4H 3452/4885EPHX2 3662/4885BCHE 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.